| Name | Title | Contact Details |
|---|
Invio Automation is a prominent provider of custom automation solutions, focusing on designing, building, and integrating advanced systems for high-growth industries. The company serves sectors such as Medical Device & Life Sciences, Renewable Energy, Mobility, Logistics & Fulfillment, and Industrial. With over 65 years of experience, Invio is headquartered in Hudson, NH, and operates seven production sites across North America. The team at Invio consists of hundreds of engineers and skilled professionals dedicated to delivering large-scale automation projects. Their offerings include robotic automation services, development of Autonomous Mobile Robots (AMRs), and a range of specialized solutions such as thermal bonding and precision dispensing. Invio also provides consulting and R&D services to help clients prepare for future automation needs. The company collaborates with a diverse customer base, supporting operations of all sizes across various industries.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Your Challenge, Our Passion.📈 Branschens i särklass vassaste stjärnor inom e-handel, digitalisering och digital affärsutveckling under ett och samma tak - Redo att accelerera Er affär. Som experter inom E-handel, digitalisering och affärsutveckling jobbar vi både stort och smått, strategiskt eller operativt – alltid med tillväxt och resultat som vårt främsta fokus. Vi stöttar Er digitala resa och identifierar var ni är idag och vart ni vill vara i framtiden – med lösningarna för att verkställa målen. Din utmaning är vår passion – vi vet vad vi pratar om, på riktigt.
Founded in 1871 in Honesdale, PA, Wayne Bank now has 26 community offices serving Wayne, Pike, Monroe, and Lackawanna Counties in Pennsylvania, along with Delaware and Sullivan Counties in New York State. Wayne Bank is a subsidiary of Norwood Financial Corp., Member FDIC. The stock trades on the NASDAQ Global Market under the symbol— NWFL.
Breckpoint is dedicated to helping brokers and employers build alternative risk solutions outside of the traditional insurance providers. For employers seeking an alternative to fully-insured group benefit plans or self-insured groups for workers compensation, Breckpoint empowers groups to take advantage of the transparency, control, and underwriting profits generated by high performing self-funded plans. - Self funded benefit administration plans - Self-insured group administration for workers compensation - Captive Management - Risk Management services We believe in Leading Together. This is the essence of Breckpoint. We are here with you through every step of this benefit journey. Your Breckpoint team provides the stellar service you deserve and we look forward to helping you manage your alternative risk programs.